The Systems Biology of Drug Resistance in Cancer group, led by professor Sampsa Hautaniemi, focuses on understanding and finding effective means to overcome drug resistance in cancers. Our approach is to use systems biology, i.e., analyze molecular & clinical data from cancer patients with machine learning and mathematical methods, to identify efficient patient-specific therapeutic targets. Our work is cross-disciplinary and done in close collaboration with researchers from various disciplines, including clinicians, cell biologists and geneticians. The main objective of our research is to obtain hypotheses and predictions that can be tested in wet-lab or in clinical trials and thereby translate medical data into benefits in cancer patient care.
Read more
@HautaniemiLab

Day 2 of the Annual DECIDER meeting was dedicated to the advisory board of the @deciderproject. We got great feedb… twitter.com/i/web/status/1…

Our poster session at the Annual DECIDER meeting in @HaltiaSuomi included 35 posters presented by 10 working groups… twitter.com/i/web/status/1…

Day 1 of the Annual DECIDER meeting got off to a good start. All participants were able to get to know each other d… twitter.com/i/web/status/1…

Our paper on #scRNAseq analysis of #chemoresistance in #ovariancancer is out today in @ScienceAdvances! Many thanks… twitter.com/i/web/status/1…